Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | GCGR | P47871 | 5/20 | 0.40 |
| ▸ | RARB | P10826 | 1/20 | 0.40 |
| ▸ | FASN | P49327 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.39 |
| ▸ | GCG | P01275 | 3/20 | 0.38 |
| ▸ | ADH5 | P11766 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7443647 | 1.00 | MCHR1 (0.42) | MCHR1SRD5A2GCGRRARBFASN | |
| SCHEMBL6418614 | 0.92 | FASN (0.44) | MCHR1SRD5A2GCGRRARBFASN | |
| SCHEMBL6418612 | 0.92 | FASN (0.44) | MCHR1SRD5A2GCGRRARBFASN | |
| SCHEMBL7440265 | 0.90 | ALDH1A1 (0.43) | GCGRRARBADH5MAP4K4 | |
| SCHEMBL7440277 | 0.90 | ALDH1A1 (0.43) | GCGRRARBADH5MAP4K4 | |
| SCHEMBL7433367 | 0.88 | APP (0.44) | RARBADH5 | |
| SCHEMBL7433362 | 0.88 | APP (0.44) | RARBADH5 | |
| SCHEMBL7446294 | 0.88 | S1PR1 (0.44) | RARB | |
| SCHEMBL7446292 | 0.88 | S1PR1 (0.44) | RARB | |
| SCHEMBL7448419 | 0.87 | ALDH1A1 (0.47) | RARBADH5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6169103-B1 | FOR TREATMENT OF ATHEROSCLEROTIC PLAQUE RUPTURE, AORTIC ANEURISM, HEART FAILURE, ULCERS, CANCER, INFLAMMATION, PAIN, ARTHRITIS, OSTEOPOROSIS, AND OTHER AUTOIMMUNE OR INFLAMMATORY DISORDERS DEPENDENT UPON TISSUE INVASION BY LEUKOCYTES | WARNER-LAMBERT | 2001-01-02 | — | — | US | claimed |
| US-6265432-B1 | CARDIOVASCULAR DISORDERS; ANTIINFLAMMATORY AGENTS; CENTRAL NERVOUS SYSTEM DISORDERS | WARNER-LAMBERT | 2001-07-24 | — | — | US | disclosed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| US-6169103-B1 | FOR TREATMENT OF ATHEROSCLEROTIC PLAQUE RUPTURE, AORTIC ANEURISM, HEART FAILURE, ULCERS, CANCER, INFLAMMATION, PAIN, ARTHRITIS, OSTEOPOROSIS, AND OTHER AUTOIMMUNE OR INFLAMMATORY DISORDERS DEPENDENT UPON TISSUE INVASION BY LEUKOCYTES | WARNER-LAMBERT | 2001-01-02 | — | — | US | disclosed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | disclosed |